Just briefly, one of the problems that joining late made perhaps, is that the focus on pharmaceuticals is all about intellectual property: let's increase intellectual property around the world. For a generic pharmaceutical industry in Canada and globally, that has a lot of problems in terms of when we can enter the market.
What we would like to see more focus on in the future is regulatory harmonization, trying to make it available so that when you develop a drug for Canada you can sell it elsewhere without having to redo tests and increase costs.
That's something I'd like to table with the committee going forward.